United Therapeutics
UTHR
459 hedge funds and large institutions have $9.35B invested in United Therapeutics in 2022 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 169 increasing their positions, 159 reducing their positions, and 62 closing their positions.
104% more call options, than puts
Call options by funds: $104M | Put options by funds: $51M
6% more repeat investments, than reductions
Existing positions increased: 169 | Existing positions reduced: 159
0.92% more ownership
Funds ownership: 97.2% → 98.12% (+0.92%)
3% less funds holding
Funds holding: 472 → 459 (-13)
10% less capital invested
Capital invested by funds: $10.4B → $9.35B (-$1.05B)
15% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 62
25% less funds holding in top 10
Funds holding in top 10: 24 → 18 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$124M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$63.7M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$54.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.6M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$35.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$54.4M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$41.7M |
| 3 |
Bank of New York Mellon
New York
|
-$39M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$36.1M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$35.5M |
UTHR Hedge Fund Activity: Q3 2022 in Review
459 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2022, worth a combined $9.35B — down 10% from $10.4B a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of UTHR and 53 opened new positions — a net loss of 9 holders — while 159 trimmed existing stakes and 169 added.
The largest buyer was Citadel Advisors, adding an estimated $124M. The largest seller was Renaissance Technologies, cutting an estimated $54.4M.
- 459 institutional investors held United Therapeutics (UTHR) as of Q3 2022, down from 472 in Q2 2022.
- Funds reported $9.35B of United Therapeutics stock for Q3 2022, down 10% quarter-over-quarter.
- 53 funds opened new United Therapeutics positions in Q3 2022 and 62 closed out, a net change of -9 holders.
- The largest United Therapeutics buyer in Q3 2022 was Citadel Advisors, an estimated $124M added.
- The largest United Therapeutics seller in Q3 2022 was Renaissance Technologies, an estimated $54.4M sold.
Based on aggregated 13F filings for Q3 2022.